GENETIC TECHNOLOGIES LIMITED — AGM Information 2011

Nov 20, 2011

==> picture [595 x 72] intentionally omitted <==

==> picture [595 x 72] intentionally omitted <==

ASX ANNOUNCEMENT November 21[st] , 2011

2011 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by Chief Executive Officer, Dr. Paul MacLeman, at the Company’s 2011 Annual General Meeting to be held at 10.00 am this morning in the “Treetops” Room at Melbourne Museum, 11 Nicholson Street, Carlton, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Thomas G. Howitt Company Secretary

Genetic Technologies Limited (ABN 17 009 212 328) Telephone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Genetic Technologies Limited Dr Paul MacLeman – CEO Address

This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward‐looking statements. By their nature, forward‐looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually

Global business

• Successful launch of BREVAGen™ in US (&EU)

• Partner with pharmaceutical companies for development of companion diagnostics

✔ (On plan)

✔

Australian operations

• Move towards critical mass for Australian sales & operations

✔

Business development and M&A

• Seek out other late stage product opportunities to market in US & Europe through existing channels

On plan

• Look for win‐win partnerships

✔

==> picture [720 x 541] intentionally omitted <==

----- Start of picture text -----

400% Market Outperform Based Upon Results
Maiden Profit &
Fund
Raising EU Debt Crisis
CLIA
BREVAGen
½ Year Profit
Launch
----- End of picture text -----

• Maiden profit and cash flow positive 2010/11

• Fund raising prior to European debt crisis strengthened balance sheet

• Decreased financing risk and ability to take advantage of M&A

• BREVAGen™ launch

• US commercial team assembled, trained and deployed

• CLIA registration attained, certification pending

• Additional quality and regulatory expertise added

• Record year for licensing revenues

• $14m gross proceeds

• Continued streamlining and cost reduction in our Australian

� The US market for existing breast cancer molecular diagnostics was approximately $690m p.a. 2007*

• Referenced by:

• BRACAnalysis (Myriad) sales

  • ~$320m p.a. in 7 years

• OncotypeDx (Genomics Health)

• ~$250m p.a. in 5 years

• Other players (Genzyme, Clarient, etc.) make up the balance

• BREVAGen™ primary US market is

a patient population of 1,000,000 patients per annum (65% of

BREVAGen™ will make a difference to 1,000’s of women

BREVAGen™ Initial Launch Territories

• Process of working through set‐up issues with insurers progressing, with recent ‘wins’

• Credentialing process with Preferred Plan Providers progressing: 10m insured lives signed up to date, others at sign‐off stage, more in late stage negotiations

• Further clinical trials and economic data

• Approximately 20 projects reviewed this year

• Detailed due diligence undertaken on two

• One project remains in mid to late stage review

• Project attributes sought are:

• Near to or on market

• Good fit to GTG’s US sales channels (OBGYNs/oncologists)

• High unmet medical need and large addressable market

• Strong reimbursement characteristics

• Strong intellectual property

Licensing: $14m Generated 2010/11

• Sales met budget despite re‐structuring

• Non‐core businesses divested

• Medical continues to be the largest growth opportunity

• Paternity sales continue to be steady, focus on maximizing margin

• Efforts to gain further forensics contracts continue

• ImmunAid and RareCellect programs to be advanced in 2012

1. Achieve BREVAGen™ sales targets

• BREVAGen™ clinical trials and expanded label claim

• Expand in major new geographies (California & Florida)

• Expansion of reimbursement agreements and ‘insured lives’ covered

• Maximize licensing opportunities

• Use strong balance sheet to acquire assets that build cancer management portfolio

• Near term revenue opportunities

• Strong Company performance for 2010/11 period under review

• CLIA registration attained

• BREVAGen launched, sales commenced

• Record licensing year

• Lean, profitable Australia operations

Dr Paul D R MacLeman CEO Genetic Technologies Ltd Phone +61 3 8412 7000 Email info@gtglabs.com